Sorin Medical Device Company Intelligence Report

Sorin develops and manufactures medical technologies and therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. At the end of 2008, the company completed a programme of strategic divestitures and concluded a plan to restructure its business portfolio. The divestitures included the sale of its endovascular, coronary stent and renal care businesses. This has allowed the company to better focus on its three core businesses – Cardiac Rhythm Management (CRM), Cardiopulmonary and Heart Valves. The CRM business produces pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy defibrillators (CRT-Ds), programmers, electrodes, electrophysiology leads and holter monitors. http://www.bharatbook.com/market-research-reports/medical-devices-market-research-report/sorin-medical-device-company-intelligence-report.html The Cardiopulmonary business produces extracorporeal blood circulation systems including oxygenators, heart-lung machines, perfusion tubing sets, autotransfusion systems and disposables, cannulae and endoscopic vessel harvesting (EVH) systems. The Heart Valves business offers mechanical heart valves, tissue heart valves, sutureless self-anchoring tissue valves and annuloplasty rings. Sorin is also a distributor of endovascular devices. Sorin’s recent investments in developing its business include the purchase of equity stakes in Enopace Biomedical (a company developing a neuromodulation system to treat patients with congestive heart failure) and MD Start (a venture capital incubator), as well as the acquisition of a line of arterial and venous cannulae from Endoscopic Technologies Inc and the purchase of Gish Biomedical (a producer of disposable medical devices for cardiovascular surgery). Sorin’s principal manufacturing and R&D facilities are located in Italy, France, Germany, Canada and the US. The company is present in more than 80 countries throughout the world and serves over 5,000 public and private health institutions. The Sorin Group was created through the demerger of Snia’s biomedical operations. It was listed separately on the Online Stock Market of the Milan Securities Exchange in January 2004. As of January 2012, its main shareholders included: Bios SpA (19.1%); Tower 6Bis Sarl (6.7%); Banca Monte Dei Paschi di Siena SpA (7.3%); Unipol Assicurazioni SpA (4.6%); GE Capital Equity Holdings (6.4%); and Norges Bank (2.0%). In 2011, Sorin generated net income of EUR58 million on sales of EUR743 million. The company employs more than 3,740 people worldwide. This company report provides Overview Key contact information Introduction to the company and its current activities Summary of its financial performance Who are the company’s major competitors? Key recent events in an “at a glance” format Financial Review Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available) Table providing in-depth five-year financial analysis Employee data, including breakdown by company division and geographic location Strategic Focus Investigates the company’s aims and its areas of focus Products Core product areas, key brands, product approvals and launches Research and Development How much has been invested in R&D? Where is the research based? What alliances and agreements does the company have and with whom? Manufacturing and Distribution Identifying the company’s manufacturing locations Sales and marketing facilities Agreements With whom has the company reached agreements and what do they involve? Key contracts awarded Mergers, Acquisitions, Minority Investments, Joint Ventures and Divestments Litigation Key Corporate Events Table of Contents OVERVIEW1 FINANCIAL REVIEW3 First Quarter 2012 Financial Results 3 2011 Financial Results 4 Cardiopulmonary6 CRM7 Heart Valves7 Sales by Geographic Region8 Five-Year Financial Data11 Outlook 12 Employees 12 STRATEGIC FOCUS13 PRODUCTS14 Cardiopulmonary 14 Heart-lung Machines15 Oxygenators16 Autotransfusion Systems16 Endoscopic Vessel Harvesting (EVH)16 Cardiac Rhythm Management (CRM)17 Pacemakers18 ICDs and CRT-Ds18 Arrhythmia Assessment Devices20 Heart Valves 20 RESEARCH AND DEVELOPMENT 23 R&D Expenditure 23 R&D Facilities 23 R&D Activities 24 Cardiopulmonary Business24 CRM Business24 Heart Valves Business25 Studies and Trials 26 DREAM Clinical Trial26 CLEAR Study26 Freedom Solo IDE Study27 ISIS-ICD Clinical Trial27 RESPOND Clinical Trial28 SonEx Clinical Trial28 MANUFACTURING 29 AGREEMENTS 30 California Medical Laboratories30 CardioMedical 30 Japan Lifeline30 Orange Business Services30 Sphere Medical31 Greatbatch31 Vertellus Biomaterials31 Medtronic32 MERGERS AND ACQUISITIONS 33 Italian Distributor33 Endoscopic Technologies Assets33 Dutch Distributor33 Gish Biomedical33 Austrian Distributor34 Dutch Distributor34 Datascope’s Endoscopic Vessel Harvesting Product Line 34 Ela Medical Cormedica Lda34 Carbomedics and Mitroflow34 Soludia34 Ela Medical35 Angeion Cardiac Stimulation Technology35 Cobe CV35 Dideco35 Bellco35 Sorin Biomedica36 MINORITY INVESTMENTS37 Enopace Biomedical 37 MD Start 37 Sphere Medical37 Other37 Istituto Europeo di Oncologia 37 Consorzio Medal Energia37 La Bouscarre SCI37 Laser und Medizin Technologie GmbH37 JOINT VENTURES 38 Ela Medical Izasa38 DIVESTITURES 39 Angel and activAT Product Lines39 Renal Care Business39 Vascular Therapy Business39 Peripheral Stent Business39 Sorin Group Japan40 Sorin LifeWatch (Telemedicine Joint Venture)40 Diagnostics Business40 Tracheostomy Products Business40 KEY CORPORATE EVENTS41 For more information kindly visit : Sorin Medical Device Company Intelligence Report.